News | July 08, 2022
WuXi STA opens Oligonucleotide and Peptide manufacturing facility
Site Enhances New Modality CRDMO Platform Capacity for Customers
Site Enhances New Modality CRDMO Platform Capacity for Customers
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Expanding US operations to address the increased demand for API development and manufacturing
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Subscribe To Our Newsletter & Stay Updated
